Skip to main content

Research Repository

Advanced Search

Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia

Woodhouse, Lisa J.; Appleton, Jason P.; Christensen, Hanne; Dineen, Rob A.; England, Timothy J.; James, Marilyn; Krishnan, Kailash; Montgomery, Alan A.; Ranta, Anna; Robinson, Thompson G.; Sprigg, Nikola; Bath, Philip M.

Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia Thumbnail


Authors

Jason P. Appleton

Hanne Christensen

ROBERT DINEEN rob.dineen@nottingham.ac.uk
Professor of Neuroradiology

MARILYN JAMES MARILYN.JAMES@NOTTINGHAM.AC.UK
Professor of Health Economics

Kailash Krishnan

ALAN MONTGOMERY ALAN.MONTGOMERY@NOTTINGHAM.AC.UK
Director Nottingham Clinical Trials Unit

Anna Ranta

Thompson G. Robinson

NIKOLA SPRIGG nikola.sprigg@nottingham.ac.uk
Professor of Stroke Medicine

PHILIP BATH philip.bath@nottingham.ac.uk
Stroke Association Professor of Stroke Medicine



Abstract

Intensive antiplatelet therapy did not reduce recurrent stroke/transient ischaemic attack (TIA) events as compared with guideline treatment in the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial, but did increase the frequency and severity of bleeding. In this pre-specified analysis, we investigated predictors of bleeding and the association of bleeding with outcome. TARDIS was an international prospective randomised open-label blinded-endpoint trial in participants with ischaemic stroke or TIA within 48h of onset. Participants were randomised to 30days of intensive antiplatelet therapy (aspirin, clopidogrel, dipyridamole) or guideline-based therapy (either clopidogrel alone or combined aspirin and dipyridamole). Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none. Of 3,096 participants, bleeding severity was: fatal 0.4%, major 1.5%, moderate 1.2%, minor 11.4%, none 85.5%. Major/fatal bleeding was increased with intensive as compared with guideline therapy: 39 vs. 17 participants, adjusted hazard ratio 2.21, 95% CI 1.24–3.93, p = 0.007. Bleeding events diverged between treatment groups in the 8–35day period but not in the 0–7 or 36–90day epochs. In multivariate analysis more, and more severe, bleeding events were seen with increasing age, female sex, pre-morbid dependency, increased time to randomisation, prior major bleed, prior antiplatelet therapy and in those randomised to triple vs guideline antiplatelet therapy. More severe bleeding was associated with worse clinical outcomes across multiple physical, emotional and quality of life domains. Trial registration ISRCTN47823388 .

Citation

Woodhouse, L. J., Appleton, J. P., Christensen, H., Dineen, R. A., England, T. J., James, M., …Bath, P. M. (2023). Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. Scientific Reports, 13, Article 11717. https://doi.org/10.1038/s41598-023-38474-2

Journal Article Type Article
Acceptance Date Jul 9, 2023
Online Publication Date Jul 20, 2023
Publication Date 2023-07
Deposit Date Jul 21, 2023
Publicly Available Date Jul 25, 2023
Journal Scientific Reports
Electronic ISSN 2045-2322
Publisher Nature Publishing Group
Peer Reviewed Peer Reviewed
Volume 13
Article Number 11717
DOI https://doi.org/10.1038/s41598-023-38474-2
Public URL https://nottingham-repository.worktribe.com/output/23219143
Publisher URL https://www.nature.com/articles/s41598-023-38474-2

Files


Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia (2.1 Mb)
PDF

Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/

Copyright Statement
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.





You might also like



Downloadable Citations